IDEMIA
The supervisory board of IDEMIA, the global leader in Augmented Identity, has appointed Yann Delabrière to be Chief Executive Officer with immediate effect taking over from Didier Lamouche who has resigned.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181015005635/en/
One year after the successful coming together of Oberthur Technologies (OT) and Safran I&S (Morpho) that gave rise to IDEMIA, Yann Delabrière will be charged with overseeing a new phase in the Group’s growth.
Yann Delabrière, who previously served as CEO of Faurecia followed by CEO of Zodiac Aerospace, was appointed IDEMIA’s supervisory board chairman in January 2018. Since then he has gained in-depth understanding of the Company’s operations and people. IDEMIA will now look to benefit from Yann’s extensive international managerial experience.
Yann Delabrière stated: “I am delighted that the Supervisory Board is entrusting me with this new role, and am excited to be leading IDEMIA as it enters the next phase of its development. IDEMIA has developed cutting-edge technologies and services leveraging artificial intelligence, biometrics and cryptography. This makes IDEMIA a major technological player in the fields of identity management and authentication or security of payments. I have witnessed IDEMIA’s growth potential first hand and believe it is excellently poised to continue to consolidate its position as the leader in the sector”
Didier Lamouche added: “During almost six years at the helm of Oberthur Technologies (OT) then IDEMIA, I am extremely proud to have contributed to building, with the teams, what has become the global leader of Augmented Identity. Together, we achieved numerous commercial successes and brought to market significant innovations, not only in the financial sector, but also with access solutions combining biometrics and remote secure communication. The successful integration of both companies, OT and Morpho, fueled by solid operational results, opens a bright future to IDEMIA and all its employees. I wish them all every success.”
Notes to Editors
About Yann Delabrière
Yann Delabrière is a graduate of the Ecole
Normale Supérieure, the Ecole Nationale d’Administration (the French
National School of Administration) and has a post-graduate degree in
mathematics. He began his career at the Committee of Public Accounts
before working in the cabinet office of the Foreign Trade Ministry. He
then worked as Financial Director of COFACE (Compagnie Française
d’Assurance pour le Commerce Extérieur, a French export credit agency)
and for the Printemps Group. In 1990, he joined the PSA Peugeot Citroën
Group as Chief Financial Officer and, in this role, became a member of
the automaker’s Executive Committee in 1998, and Chairman and CEO of the
Group’s consumer finance unit, Banque PSA Finance. Yann Delabrière was
appointed as Chairman and Chief Executive Officer of Faurecia in 2007.
He was also Chairman of the Executive Board of Zodiac Aerospace between
June 2017 and February 2018. He has been a member of the Board of
Directors of Cap Gemini from 2004 to May 2018, a member of the Board of
Directors of Société Générale from 2012 to 2016, and member of the Board
of Directors of Alstom since March 2017. He has headed IDEMIA’s
Supervisory Board since January 2018.
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with
the ambition to provide a secure environment enabling citizens and
consumers alike to perform their daily critical activities (such as pay,
connect, travel and vote), in the physical as well as digital space.
Securing
our identity has become mission critical in the world we live in today.
By standing for Augmented Identity, we reinvent the way we think,
produce, use and protect this asset, whether for individuals or for
objects. We ensure privacy and trust as well as guarantee secure,
authenticated and verifiable transactions for international clients from
Financial, Telecom, Identity, Public Security and IoT sectors.
OT
(Oberthur Technologies) and Safran Identity & Security (Morpho) have
joined forces to form IDEMIA. With close to $3 billion in revenues and
14,000 employees around the world, IDEMIA serves clients in 180
countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20181015005635/en/
Contact:
IDEMIA Press Hanna Sebbah: idemia@havas.com +33 (0)6 63 73 30 30
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Blind Sailor Takes the Stage at WEF: "HIRO’s CHOICE" Project to Set Sail13.1.2026 05:00:00 CET | Press release
A Solo, Non-Stop Crossing of the Pacific Ocean “Blind Sailor Single-Handed Pacific Crossing Project 2027” is a world-first initiative in which Mitsuhiro Iwamoto, a completely blind Japanese yachtsman (blind sailor) based in San Diego, will attempt a solo, non-stop trans-Pacific crossing in the spring of 2027. Sailing a 28-foot yacht single-handedly, he aims to cross the Pacific Ocean from San Diego on the U.S. West Coast to Amakusa, Kumamoto Prefecture, Japan, without making port. Iwamoto will speak about this project at the World Economic Forum Annual Meeting 2026, to be held in January 2026. Project URL: https://hiros-choice.com/ This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108087321/en/ Hiro Iwamoto / Global Keynote Speaker, First Totally Blind Sailor to Cross the Pacific The message he most wishes to convey at the WEF is the power of choice. He lost his sight at the age of sixteen—a moment when he nearly gave up on
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
